SIYDIK KISLOTALI BUYRAK TOSHLARINING ETIOPATOGENEZI VA DAVOLASH USULLARI

SIYDIK KISLOTALI BUYRAK TOSHLARINING ETIOPATOGENEZI VA DAVOLASH USULLARI

Authors

  • Boyqulov To‘rabek Temirovich Termiz iqtisodiyot va servis universiteti Morfologik fanlar kafedrasi o‘qituvchisi.
  • Ashurov Sirojiddin Toshkent davlat tibbiyot universiteti Termiz filiali Umumiy xirurgiya, bolalar xirurgiyasi, urologiya va bolalar urologiyasi kafedrasi.
  • Xolboyev Norbek Aliniyozovich Termiz iqtisodiyot va servis universiteti Terapevtik fanlar kafedrasi o‘qituvchisi.

Keywords:

urolitiaz, siydik kislotali nefrolitiaz, giperurikozuriya, podagra.

Abstract

So‘nggi o‘n yilliklarda rivojlanyotgan mamlakatlarda urolitiazning tarqalish darajasi ortib bormoqda. Siydik kislotali toshlar buyrak toshlarining sezilarli qismini tashkil etadi. Siydik kislotali nefrolitiazning patogenezida ayrim xavf omillari, jumladan giperurikozuriya, siydik hajmining kamayishi va doimiy ravishda past siydik pH darajasi ishtirok etadi. Patologik holatlar natijasida chuqur giperurikozuriya rivojlanadigan bemorlar siydik kislotali toshlar hosil bo‘lishi yuqori darajali xavf guruhiga kiradilar. Bunday holatlarga surunkali diareya bilan kechuvchi sindromlar, miyeloproliferativ kasalliklar, insulin rezistentligi (shu jumladan, qandli diabet) hamda monogen metabolik buzilishlar, masalan Lesh–Nihan sindromi, kiradi. Kompyuter tomografiyasi (KT) siydik kislotali toshlarni aniq tashxislash imkonini beradi. Og‘ir obstruksiya, progressiv azotemiya, jiddiy infeksiya yoki to‘xtovsiz og‘riq kuzatilmagan hollarda bunday bemorlarning boshlang‘ich davosi sifatida tibbiy dissolyutsiya (dorilar bilan eritish) terapiyasi tavsiya etiladi, chunki bu yondashuv aksariyat hollarda samarali hisoblanadi.

Siydik kislotali nefrolitiazning epidemiologiyasi va patofiziologiyasini batafsil o‘rganish bu kasallik bilan og‘rigan bemorlarda toshlarning to‘g‘ri tashxisi, davolash va profilaktikasi uchun muhim ahamiyatga ega.

References

1. Moe OW. Uric acid nephrolithiasis: proton titration of an essential molecule? Curr Opin Nephrol Hypertens. 2006;15:366-373.

2. Gianfrancesco F, Esposito T, Ombra MN, et al.Identification of a novel gene and a commonvariant associated with uric acid nephrolithiasis

in a Sardinian genetic isolate. Am J Hum Genet.2003;72:1479-1491.

3. Moe OW. Kidney stones: pathophysiology andmedical management. Lancet. 2006;367:333-344.

4. Stamatelou KK, Francis ME, Jones CA, et al.Time trends in reported prevalence of kidneystones in the United States: 1976-1994. Kidney Int. 2003;63:1817-1823.

5. Pearle MS, Calhoun EA, Curhan GC. Urologic Diseases of America Project: Urolithiasis. J Urol. 2005;173:848-857.

6. Portis AJ, Hermans K, Culhane-Pera KA, Curhan GC. Stone disease in the Hmong of Minnesota: initial description of a high-risk population. J

Endourol. 2004;18:853-857.

7. Maloney ME, Springhart WP, Ekeruo WO, et al. Ethnic background has minimal impact on the etiology of nephrolithiasis. J Urol. 2005;173:

2001-2004.

8. Ansari MS, Gupta NP, Hemal AK, et al. Spectrum of stone composition: structural analysis of 1050 upper urinary tract calculi from northern India. Int J Urol. 2005;12:12-16.

9. Hossain RZ, Ogawa Y, Hokama S, et al. Urolithiasis in Okinawa, Japan: a relatively high prevalence of uric acid stones. Int J Urol. 2003;10:411-415.

10. Atan L, Andreoni C, Ortiz V, et al. High kidney stone risk in men working in steel industry at hot temperatures. Urology. 2005;65:858-861.

11. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002; 19:640-653.

12. Benzie IF. Evolution of antioxidant defense mechanisms. Eur J Nutr. 2000;39:53-61.

13. Drulovic J, Dujmovic I, Stojsavljevic N, et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol. 2001;248:121-126.

14. Martinon F, Petrilli V, Mayor A, et al. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-241.

15. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol.

2005;16:1909-1919.

16. Anzai N, Enomoto A, Endou H. Renal urate handling: clinical relevance of recent advances. Curr Rheumatol Rep. 2005;7:227-234.

17. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447-452.

18. Lipkowitz MS, Leal-Pinto E, Rappoport JZ, et al. Functional reconstitution, membrane targeting, genomic structure and chromosomal localization

of a human urate transporter. J Clin Invest. 2001;107:1103-1115.

19. Evan AP, Lingeman JE, Coe FL, et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003;111:607-616.

20. Kim SC, Coe FL, Tinmouth WW, et al. Stone formation is proportional to papillary surface coverage by Randall’s plaque. J Urol. 2005;173:117-119.

21. Evan A, Lingeman J, Coe FL, Worcester E. Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int.2006;69:1313-1318.

22. Pak CY, Poindexter JR, Peterson RD, et al. Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Urology. 2002;60:789-794

Downloads

Published

2025-12-13

How to Cite

To‘rabek Temirovich , B., Sirojiddin , A., & Norbek Aliniyozovich , X. (2025). SIYDIK KISLOTALI BUYRAK TOSHLARINING ETIOPATOGENEZI VA DAVOLASH USULLARI. SCHOLAR, 3(15), 202–219. Retrieved from https://scholar-journal.org/index.php/scholar/article/view/174

Issue

Section

Articles
Loading...